Medical Condition News

RSS

Acetylon receives U.S. patent for ACY-1215 to treat multiple myeloma

Acetylon Pharmaceuticals Inc. today announced that it has been granted U.S. Patent 8,148,526 by the United States Patent and Trademark Office (USPTO). This patent contains fundamental composition of matter claims covering the Company's selective HDAC6 inhibitor, ACY-1215, which is currently being investigated in human clinical trials for the treatment of multiple myeloma.

21 Apr 2012

EMA CHMP recommends approval of AMAG’s ferumoxytol

AMAG Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the approval of ferumoxytol, an intravenous (IV) iron therapy, for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

21 Apr 2012

Significant gaps in public awareness about cardiovascular risks from tobacco use, secondhand smoke

A report released today at the World Heart Federation World Congress of Cardiology in Dubai reveals significant gaps in public awareness regarding the cardiovascular risks of tobacco use and secondhand smoke. The report, entitled "Cardiovascular harms from tobacco use and secondhand smoke", was commissioned by the World Heart Federation and written by the International Tobacco Control Project (ITC Project), in collaboration with the Tobacco Free Initiative at the World Health Organization.

21 Apr 2012

Scientists discover tumor-targeting neural stem cells

Could engineered human stem cells hold the key to cancer survival? Scientists at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, have discovered that neural stem cells possess the innate ability to target tumor cells outside the central nervous system. This finding, which was demonstrated successfully on breast cancer cells, was recently published in leading peer reviewed journal, Stem Cells.

21 Apr 2012

Results from Boehringer Ingelheim's afatinib Phase III lung cancer trial

Highly anticipated results from LUX-Lung 3, the pivotal Phase III lung cancer trial investigating Boehringer Ingelheim's front running oncology investigational compound, the ErbB Family Blocker afatinib, in patients with EGFR mutations, will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 1 - 5 June 2012.

21 Apr 2012

Researchers uncover 22 new genes linked with autism, other neurodevelopmental disorders

When chromosomes replicate, sometimes there is an exchange of genetic material within a chromosome or between two or more chromosomes without a significant loss of genetic material. This exchange, known as a balanced chromosomal abnormality (BCA), can cause rearrangements in the genetic code.

21 Apr 2012

Study finds under-treatment of RHD in India, Africa

Rheumatic heart disease (RHD) is significantly under-treated in Africa and India according to the preliminary findings of a new global study presented today at the World Congress of Cardiology.

21 Apr 2012

Updated results from CircuLite’s Synergy miniature ventricular support system clinical study

CircuLite, Inc. today announced that updated clinical data related to the Synergy miniature ventricular support system was presented in two oral presentations and one poster session at the International Society for Heart and Lung Transplantation's 32nd Annual Meeting and Scientific Sessions (ISHLT) in Prague, Czech Republic.

21 Apr 2012

First study to examine soda's effect on stroke risk

Researchers from Cleveland Clinic's Wellness Institute and Harvard University have found that greater consumption of sugar-sweetened and low-calorie sodas is associated with a higher risk of stroke. Conversely, consumption of caffeinated or decaffeinated coffee was associated with a lower risk.

21 Apr 2012

Liver can directly talk to the brain to control amount of food we eat

Dr Barbara Fam from the University's Molecular Obesity Laboratory group at Austin Health with Associate Professor Sof Andrikopoulos have discovered that the liver can directly talk to the brain to control the amount of food we eat.

21 Apr 2012

Perivascular fat tissue may influence onset of atherosclerosis

Researchers at UC have confirmed that fat surrounding the outside of arteries in humans-particularly the left coronary artery-may influence the onset of coronary artery disease, or atherosclerosis, which is the leading cause of death in the U.S.

21 Apr 2012

Exercise may help smokers to quit, reduce risk of CVD

Exercise may help smokers to quit and remain smokefree, according to new data presented today at the World Congress of Cardiology. Moreover, exercise increases life expectancy in smokers and non-smokers alike.

21 Apr 2012

SEBM announces 2012 winners of Young Investigator Award

The Society for Experimental Biology and Medicine is pleased to announce the 2012 winners of the Young Investigator Award. This is a $500 travel grant for undergraduate/ graduate students and/or individuals within 5 years of receiving doctoral degrees who are members of the Society to attend the Experimental Biology meeting in San Diego this month.

21 Apr 2012

First study to quantify effects of AD plaques on brain networks in animal model

Scientists studying the way Alzheimer's takes root in the brain have identified important new similarities between a mouse model and human Alzheimer's.

21 Apr 2012

Sequana Medical's ALFApump System safe and effective in managing ascites

Sequana Medical announced that initial results from the PIONEER Clinical Study of its ALFApump System were presented today at the 47th annual European Association for Study of the Liver Meeting in Barcelona.

21 Apr 2012

Large doses of vitamin C may moderately reduce blood pressure

Taking large doses of vitamin C may moderately reduce blood pressure, according to an analysis of years of research by Johns Hopkins scientists. But the researchers stopped short of suggesting people load up on supplements.

21 Apr 2012

Researchers discover novel genetic mechanism of idiopathic CD4 lymphopenia

Researchers at National Jewish Health have discovered a novel genetic mechanism of immune deficiency. Magdalena M. Gorska, MD, PhD, and Rafeul Alam, MD, PhD, identified a mutation in Unc119 that causes immunodeficiency known as idiopathic CD4 lymphopenia.

21 Apr 2012

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive results from its Phase I clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

21 Apr 2012

Depression may increase risk of peripheral artery disease

Depression may be associated with an increased risk of arterial narrowing in the legs and pelvis, a condition known as peripheral artery disease (PAD), according to research presented at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology 2012 Scientific Sessions in Chicago.

21 Apr 2012

ACT announces dosing of third patient in dry AMD Phase I/II trial

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today the dosing of the third patient in its Phase I/II trial for dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells.

21 Apr 2012